Arbutus Biopharma Corp (ABUS) Stock Price, Chart & News

Earn 10$ Cash for every Pro+ Friend you Refer!

ABUS

3.20

USD-0.15-4.43%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Insider Trades

Filings

News

Chart

Latest News

@eWhispers

3 years

#earnings before the open tomorrow https://t.co/lObOE0dgsr $MRNA $PENN $VIAC $NKLA $GOLD $REGN $W $HIMX $LSPD $BLDR $DOCN $CI $VSTO $CYBR $LNG $PWR $RGS $PLNT $K $ERJ $FIS $DISH $PZZA $CARS $DNB $DUK $MBUU $CTXS $AHCO $VMC $GEO $EPAM $CHH $ABC $APD $BXRX $IRM $LITE $ABUS $SO https://t.co/fIMvfKVlk4

Analysts Recommendations

Bullish

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

3.18USD

3.38USD

52 Week Range

2.21USD

4.72USD

Market Cap

634.8MUSD

About

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

CA03879J1003

CUSIP

87911B209

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

0.56

Dividend Share

Dividend Yield

Earnings Share

-0.43

Wall Street Target Price

5.1307

EPS Estimate Current Year

-0.5478

EPS Estimate Next Year

-0.47

EPS Estimate Current Quarter

-0.09

EPS Estimate Next Quarter

-0.08

Most Recent Quarter

Profitability

Revenue TTM

6,742,000

Gross Profit TTM

-56,049,000

EBITDA

-77,140,000

Profit Margin

0.00%

Return On Assets TTM

-32.83%

Return On Equity TTM

-67.81%

Revenue Per Share TTM

0.037

Qtly Revenue Growth YOY

-71.30%

Diluted Eps TTM

-0.43

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

89.3777

Price Book MRQ

5.6374

Enterprise Value Revenue

Enterprise Value EBITDA

-5

Peers analysis

CMXHFCSL Limited
169.54
3.19%
CSLLYCSL Ltd
86.83
0.51%
ALNYAlnylam Pharmaceuticals Inc
241.51
0.44%
BNTXBioNTech SE
112.72
0.41%
VRTXVertex Pharmaceuticals Inc
412.01
0.08%

ARGNFargenx SE
655.00
0.00%
UCBJFUCB SA
194.85
0.00%
REGNRegeneron Pharmaceuticals Inc
694.00
-3.22%
ARGXargenx NV ADR
659.01
-1.00%
UCBJYUCB SA ADR
97.63
-0.27%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2025